Breast cancer deaths in the US continue to fall, but new report …
WEB4 days ago — The study, published Tuesday in CA: A Cancer Journal for Clinicians, found some good news: The overall breast cancer death rate in the US dropped about 44% between 1989 and 2022, which translates ...
Press Releases - pressroom.cancer.org
WEB5 days ago — ATLANTA, October 1, 2024 — The American Cancer Society (ACS) today released Breast Cancer Statistics, 2024, the organization’s biennial update on breast cancer occurrence and trends in the United States. The new report finds breast cancer mortality rates overall have dropped by 44% since 1989, averting approximately 517,900 breast cancer deaths. . However, not all women have benefited from ...
New study finds triple-negative breast cancer tumors with an …
WEBApr 25, 2024 — A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates even when not treated with chemotherapy.
Breast Cancer Incidence Still Rises and Death Rate Still Declines
WEB4 days ago — A new American Cancer Society (ACS) report finds that the incidence of breast cancer in women has continued to increase, rising by 1% a year during 2012 to 2021, for all women combined. These cases are largely confined to localized-stage cancers, which have not spread from the breast, and hormone receptor-positive disease (either estrogen positive or progesterone positive), the most common ...
Breast Cancer News - ScienceDaily
WEB2 days ago — Breast cancer research including information on breast cancer symptoms, prevention strategies, screening techniques, and new breast cancer treatments.
Estrogen a more powerful breast cancer culprit than we realized
WEBMay 17, 2023 — A Harvard Medical School study shows the sex hormone estrogen — thus far thought to be only a fuel for breast cancer growth — can directly cause tumor-driving genomic rearrangements.
Breast Cancer Drug Trial Results in ‘Unheard-Of’ Survival
WEBJun 7, 2022 — The clinical trial, sponsored by the pharmaceutical companies Daiichi Sankyo and AstraZeneca and led by Dr. Shanu Modi of Memorial Sloan Kettering Cancer Center, involved 557 patients with...
Experimental immunotherapy targets metastatic breast cancer
WEBFeb 1, 2022 — Many people with metastatic breast cancer can mount an immune reaction against their tumors, the study found, a prerequisite for this type of immunotherapy, which relies on what are called tumor-infiltrating lymphocytes (TILs).
Targeting HER2-positive breast cancer: advances and future …
WEBNov 7, 2022 — The long-sought discovery of HER2 as an actionable and highly sensitive therapeutic target was a major breakthrough for the treatment of highly aggressive HER2-positive breast cancer, leading...
Pembrolizumab for Advanced Triple-Negative Breast Cancer
WEBAug 9, 2022 — In the KEYNOTE-355 trial, 847 patients with advanced (unresectable, locally advanced, or metastatic) triple-negative breast cancer were randomly assigned to receive chemotherapy plus placebo or chemotherapy plus pembrolizumab.